Fate Therapeutics (FATE) Common Equity (2012 - 2026)
Fate Therapeutics' (FATE) quarterly Common Equity came in at $179.7 million in Q1 2026, down 37.69% YoY from $288.4 million in Q1 2025, and down 13.26% on a QoQ basis from $207.2 million in Q4 2025.
Fate Therapeutics (FATE) Common Equity (2012 - 2026) Analysis & Trends
Fate Therapeutics (FATE) has 15 years of Common Equity data on file, last reported at $179.7 million in Q1 2026.
- Quarterly Common Equity fell 37.69% year-over-year to $179.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $179.7 million (down 37.69% YoY) and the FY2025 annual result came in at $207.2 million, down 35.0% from the prior year.
- Common Equity slipped to $179.7 million in Q1 2026, from $207.2 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $633.4 million in Q1 2022 to a low of $179.7 million in Q1 2026.
- A 5-year average of $386.9 million and a median of $397.0 million in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2024 — Common Equity fell 9.31% — and 2026, when it plunged 37.69%.
- Tracing FATE's Common Equity over 5 years: stood at $483.9 million in 2022, then decreased by 23.87% to $368.4 million in 2023, then slipped by 13.49% to $318.7 million in 2024, then sank by 35.0% to $207.2 million in 2025, then fell by 13.26% to $179.7 million in 2026.
- The last three Common Equity figures came in at $179.7 million (Q1 2026), $207.2 million (Q4 2025), and $234.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Fate Therapeutics | 298.82 Mn | 298.82 Mn | - | 179.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 179.71 Mn |
| Dec 31, 2025 | 207.18 Mn |
| Sep 30, 2025 | 234.07 Mn |
| Jun 30, 2025 | 261.36 Mn |
| Mar 31, 2025 | 288.41 Mn |
| Dec 31, 2024 | 318.73 Mn |
| Sep 30, 2024 | 362.33 Mn |
| Jun 30, 2024 | 396.98 Mn |
| Mar 31, 2024 | 426.12 Mn |
| Dec 31, 2023 | 368.42 Mn |
| Sep 30, 2023 | 402.78 Mn |
| Jun 30, 2023 | 437.76 Mn |
| Mar 31, 2023 | 477.47 Mn |
| Dec 31, 2022 | 483.94 Mn |
| Sep 30, 2022 | 518.00 Mn |
| Jun 30, 2022 | 580.48 Mn |
| Mar 31, 2022 | 633.39 Mn |
| Dec 31, 2021 | 678.84 Mn |
| Sep 30, 2021 | 730.33 Mn |
| Jun 30, 2021 | 752.07 Mn |